To date, a combined total of 32 claims have been deemed novel
for the core technology of the INSPIRA™ ART device
Targeting treatment for 20 million ICU patients with respiratory
failure annually, with many relying on mechanical ventilators, in a
$19 billion industry
RA'ANANA, Israel, Sept. 13,
2024 /PRNewswire/ -- Inspira™ Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the
"Company" or "Inspira Technologies"), a breakthrough medical
technology company targeting to supersede mechanical ventilators,
has secured an additional U.S. Patent approval for the
VORTX™ orbiting blood oxygenation delivery system, a core
technology of the revolutionary INSPIRA™ ART device, bringing the
combined total of claims deemed novel relating to the core
technology of the INSPIRA™ ART device, to 32.
The VORTX™ system aims to oxygenate blood without fiber
membranes, potentially transforming the medical field as this
technology is expected to reduce both blood damage and costs.
Today's fiber technologies for blood oxygenation significantly harm
the patient's blood cells, since existing fiber oxygenators force
blood to flow through multiple fiber layers, causing harmful
turbulence, friction, and shear forces. Due to the fiber fabric's
high resistance to blood flow, it creates pressure differences that
can severely damage blood components, potentially causing
hemolysis, white blood cell damage, inflammatory and immune system
activation, and blood clotting.
Dagi Ben-Noon, CEO of Inspira Technologies, remarked, "We
view this as another major leap forward in blood oxygenation
technologies, representing another crucial milestone highlighting
the core technological capabilities of the INSPIRA™ ART."
We believe the INSPIRA™ ART is a groundbreaking device poised to
revolutionize the $19 billion
mechanical ventilation market. Designed to support the 20 million
intensive care unit patients with respiratory failure each year,
many of whom rely on mechanical ventilators, the INSPIRA™ ART
offers a potential alternative by maintaining stable oxygen
saturation levels without the need for ventilators while patients
can remain awake during treatment.
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA™
ART), with adaptive blood monitoring and blood oxygenation
technology designed to rebalance patient oxygen saturation levels.
This technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. Equipped with HYLA™ real-time continuous
blood monitoring technology, the system instantly detects changes
in patient conditions, empowering physicians in making informed
decisions.
The Company's INSPIRA™ ART100 system has
obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass
procedures, along with the Israeli AMAR certification for both
Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass
procedures.
The Company's other products, including the INSPIRA™ ART also
known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART
portable modular device and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses intended benefits and
uses of its technology, the number of potential patients, and
potential market size, that may utilize its technology and
products, the belief that the patent is a major leap forward in
blood oxygenation technologies, representing another crucial
milestone highlighting the core technological capabilities of the
INSPIRA and the belief that the INSPIRA ART is an innovative
device set to transform the $19
billion mechanical ventilation industry. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov.
MRK-ARS-116
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
For more details:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
View original
content:https://www.prnewswire.com/news-releases/inspira-secures-a-second-us-patent-approval-for-orbiting-blood-oxygenation-delivery-system-302247625.html
SOURCE Inspira Technologies